New drug cocktail aims to prevent rare liver Cancer's return after surgery
NCT ID NCT07243951
First seen Jan 04, 2026 · Last updated May 13, 2026 · Updated 19 times
Summary
This study tests whether combining an immunotherapy drug (cadonilimab) with a chemotherapy pill (capecitabine) can keep a rare, aggressive liver cancer from returning after surgery. About 75 patients with mixed liver cancer who had their tumor fully removed will receive the combo for up to 6 months. Researchers will track how long patients stay cancer-free and monitor side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.